Kenichi Ogasawara

Extensive polymorphism of ABO blood group gene: three major lineages of the alleles for the common ABO phenotypes

Polymorphism of the ABO blood group gene was investigated in 262 healthy Japanese donors by a polymerase chain reactions-single-strand conformation polymorphism (PCR-SSCP) method, and 13 different alleles were identified. The number of alleles identified in each group was 4 for A1 (provisionally called ABO*A101, *A102, *A103 and *A104 according to the guidelines for human gene nomenclature), 3 for B (ABO*B101, *B102 and *B103), and 6 for O (ABO*O101, *O102, *O103, *O201, *O202 and *O203). Nucleotide sequences of the amplified fragments with different SSCP patterns were determined by direct sequencing. Phylogenetic network analysis revealed that these alleles could be classified into three major lineages, *A/*O1, *B and *O2. In Japanese, *A102 and *13101 were the predominant alleles with frequencies of 83% and 97% in each group, respectively, whereas in group O, two common alleles, *O101 (43%) and *O201 (53%), were observed. These results may be useful for the establishment of ABO genotyping, and these newly described ABO alleles would be advantageous indicators for population studies.

Recombination and gene conversion-like events may contribute to ABO gene diversity causing various phenotypes

Abstract. We identified five different alleles, tentatively named ABO*O301, *O302, *R102, *R103, and *A110, in Japanese individuals possessing the blood group O phenotype. These alleles lack the guanine deletion at nucleotide position 261 which is shared by a majority of O alleles. Nucleotide sequence analysis revealed that *O301 and *O302 had single nonsynonymous substitutions compared with *A101 or *A102 responsible for the A1 phenotype. Analysis of intron 6 at the ABO gene by polymerase chain reaction-single-strand conformation polymorphism and direct sequencing revealed that *R102 and *R103 had chimeric sequences of A-O2 and B-O2, respectively, from exons 6 to 7. In the analysis of five other chimeric alleles detected in the same manner, we identified a total of four different recombination-breakpoints within or near intron 6. When 510 unrelated Japanese were examined, the frequency of the chimeric alleles generated by recombination in intron 6 or exon 7 was estimated to be 1.7%. In addition, we found that *O301, *A110, *C101, *A111, and 35% of *A102 had a unique A-B-A chimeric sequence at intron 6, presumed to originate from a gene conversion-like event. We had previously established that *A110 also had an A-O2-A chimeric sequence around nucleotide position 646 in exon 7. Thus this allele has an A-B-A-O2-A chimeric sequence from intron 6 to exon 7 probably generated by two different gene conversions. Similar patchwork sequences around nucleotide position 646 in exon 7 were observed in two other new alleles responsible for the Ax and B3 phenotypes. Thus, the site is presumably a hotspot for gene conversion. These results indicate that both recombination and gene conversion-like events play important roles in generating ABO gene diversity.

Different alleles cause an imbalance in A2 and A2B phenotypes of the ABO blood group

Background and Objectives: In several populations, including the Japanese, the frequency of the A2B phenotype is significantly higher than expected based on the A2 phenotype frequency. To understand the genetic basis of this ‘excess’ of A2B, we examined ABO alleles in individuals with A2‐related phenotypes. Materials and Methods: ABO alleles were identified by means of polymerase chain reaction single‐strand conformation polymorphism (SSCP) and nucleotide sequence analyses. Results: The frequencies of A2‐related alleles (*A105, *A106, *A107, *A111 and *R101) were clearly different between the A2 and A2B phenotypes. In particular, a putative recombinant allele, *R101, was uncommon in the A2 but common in the A2B phenotype individuals. This allele was also detected in 4 of 401 (1%) unrelated A1 phenotype (AO genotype) individuals. Conclusion: *R101 is presumably expressed as phenotype A1 in *R101/*O heterozygous individuals, but as phenotype A2 in *R101/*B heterozygotes, thus giving rise to a high A2B phenotype frequency.

Expression of ABO blood-group genes is dependent upon an erythroid cell-specific regulatory element that is deleted in persons with the B(m) phenotype.

The ABO blood group is of great importance in blood transfusion and organ transplantation. However, the mechanisms regulating human ABO gene expression remain obscure. On the basis of DNase I-hypersensitive sites in and upstream of ABO in K562 cells, in the present study, we prepared reporter plasmid constructs including these sites. Subsequent luciferase assays indicated a novel positive regulatory element in intron 1. This element was shown to enhance ABO promoter activity in an erythroid cell-specific manner. Electrophoretic mobility-shift assays demonstrated that it bound to the tissue-restricted transcription factor GATA-1. Mutation of the GATA motifs to abrogate binding of this factor reduced the regulatory activity of the element. Therefore, GATA-1 appears to be involved in the cell-specific activity of the element. Furthermore, we found that a partial deletion in intron 1 involving the element was associated with B(m) phenotypes. Therefore, it is plausible that deletion of the erythroid cell-specific regulatory element could down-regulate transcription in the B(m) allele, leading to reduction of B-antigen expression in cells of erythroid lineage, but not in mucus-secreting cells. These results support the contention that the enhancer-like element in intron 1 of ABO has a significant function in erythroid cells.

A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein

Background and Objectives  Rh‐associated glycoprotein (RhAG) is closely associated with the Rh proteins in the red cell membrane. Two high frequency antigens (Duclos and DSLK) and one low frequency antigen (Ola) have serological characteristics suggestive of expression on RhAG.

Mutation of the GATA site in the erythroid cell–specific regulatory element of the ABO gene in a Bm subgroup individual

The ABO blood group is important in blood transfusion. Recently, an erythroid cell–specific regulatory element has been identified in the first intron of ABO using luciferase reporter assays with K562 cells. The erythroid cell–specific regulatory activity of the element was dependent upon GATA‐1 binding. In addition, partial deletion of Intron 1 including the element was observed in genomic DNAs obtained from 111 Bm and ABm individuals, except for one, whereas the deletion was never found among 1005 individuals with the common phenotypes.

Deletion of the RUNX1 binding site in the erythroid cell-specific regulatory element of the ABO gene in two individuals with the Am phenotype.

An erythroid cell‐specific regulatory element, referred to as the +5·8‐kb site, had been identified in the first intron of the human ABO blood group gene. Subsequent studies revealed that either a 5·8‐kb deletion including the +5·8‐kb site or disruption of a GATA factor binding motif at the site was present in all Bm and ABm individuals examined. We investigated the molecular mechanism of the Am phenotype, which is analogous to the Bm phenotype.

Consequences of Nucleic Acid Amplification Testing for Blood Transfusion Centres

This article is also accessible online at: http://BioMedNet.com/karger Blood banks and transfusion centres are faced with the imminent introduction of nucleic acid amplification testing (NAT), or genomic amplification testing of plasma pools used by the plasma industry. The Committee for Proprietary Medicinal Products (CPMP) in Europe requires that all manufactured plasma pools should be tested for HCV RNA by NAT by July 1, 1999. To avoid the destruction of large NAT-reactive plasma pools, the CPMP strongly advises to implement a system for the screening of minipools of plasma by NAT. In future, genomic screening of individual donations for blood-borne viruses is expected to become obligatory. At present, genomic screening of individual donations cannot be routinely performed, and NAT minipool screening (i.e. a pool of plasma of 100 donations) is not (well) standardized, is costly and time-consuming, especially when the individual positive donors from a positive pool have to be sorted out. An especially difficult and ethical question is what should be decided concerning the release of red cell products and especially platelets when minipool screening is implemented. Either these cellular products will be blocked for at least several days, creating shortage and loss of product, or the results of minipool screening tests will not affect these products. This may create different levels of safety and serious ethical problems by informing (or not informing) recipients of these products after a positive result has been obtained. Fourteen experts in the field were asked for their opinion, answers were obtained from 10 of them on the following questions.

Molecular basis for D− Japanese: identification of novel DEL and D− alleles

The occurrence of D− is approximately 0·5% in Japanese, but DEL in apparently D− individuals is relatively common compared with that in Caucasian populations. On the basis of molecular genetics, we examined D− Japanese blood donors.

JK null alleles identified from Japanese individuals with Jk(a−b−) phenotype

The Kidd blood group system consists of three common phenotypes: Jk(a+b−), Jk(a−b+) and Jk(a+b+), and one rare phenotype, Jk(a−b−). Jka/Jkb polymorphism is associated with c.838G>A (p.Asp280Asn) in exon 9 of the JK (SLC14A1) gene, and the corresponding alleles are named JK*01 and JK*02. The rare phenotype Jk(a−b−) was first found in a Filipina of Spanish and Chinese ancestry, and to date, several JK null alleles responsible for the Jk(a−b−) phenotype have been reported. We report seven novel JK null alleles, 4 with a JK*01 background and 3 with a JK*02 background, identified from Jk(a−b−) Japanese.